Evidence map›Paper›PMID 35157737›Full record

ArticlePloS one2022

Final HIV status outcome for HIV-exposed infants at 18 months of age in nine states and the Federal Capital Territory, Nigeria.

Babatunde Adelekan, Bidemi Harry-Erin, Martha Okposo, Ahmad Aliyu, Nicaise Ndembi, Patrick Dakum, Nadia A Sam-Agudu

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Roadmap for Achieving Universal Antiretroviral Treatment.Annual review of pharmacology and toxicology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Babatunde AdelekanStrategic Information, Institute of Human Virology Nigeria, Abuja, Nigeria.
Bidemi Harry-ErinStrategic Information, Institute of Human Virology Nigeria, Abuja, Nigeria.ORCID 0000-0002-9292-2955
Martha OkposoStrategic Information, Institute of Human Virology Nigeria, Abuja, Nigeria.
Ahmad AliyuStrategic Information, Institute of Human Virology Nigeria, Abuja, Nigeria.
Nicaise NdembiLaboratory Research, Institute of Human Virology Nigeria, Abuja, Nigeria.
Patrick DakumDepartment of Pediatrics, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Nadia A Sam-AguduDepartment of Pediatrics, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.ORCID 0000-0001-5052-7730
Institute of Human Virology · NGUniversity of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhile antiretroviral therapy (ART) coverage for pregnant women has undergone steady scale-up, Nigeria's final mother- to-child transmission of HIV (MTCT) rate remains unacceptably high at 10%. This study aimed to determine final outcomes (MTCT rates) and their correlates among HIV-exposed infants (HEI) in nine states and the Federal Capital Territory, Nigeria.

methodsThis retrospective, cross-sectional study was conducted at 96 primary, secondary and tertiary health facilities supported by the Institute of Human Virology Nigeria. Data was abstracted for a birth cohort of HEI born between October 30, 2014 and April 30, 2015 whose 18-24 month final outcome was assessed by October 30, 2016. Only infants with a six-week first DNA PCR result, and a rapid HIV antibody test result at age 18 to 24 months were included. Multivariate logistic regression (adjusted odds ratios [aORs]) evaluated for predictors of HIV positivity at ≥18 months.

resultsAfter testing at ≥18 months, 68 (2.8%) of the 2,405 exposed infants in the birth cohort were HIV-positive. After a minimum of 18 months of follow-up, 51 (75%) HIV-positive infants were alive on ART; 7 (10%) had died, 5 (7.3%) were lost to follow-up and 5 (7.3%) were transferred out. Rural maternal residence, lack of maternal ART/ARV prophylaxis, mixed infant feeding and infant birth weight less than 2.5 kg correlated with an HIV-positive status for infant final outcomes.

conclusionThe final HIV positivity rate of 2.8% is encouraging, but is not population-based. Nevertheless, supported by our findings, we recommend continued programmatic focus on early access to quality prenatal care and maternal ART for pregnant women, especially for women living with HIV in rural areas. Furthermore, implementation of nationwide sensitization and education on six-months' exclusive infant breastfeeding with concurrent maternal ART should be strengthened and sustained to reduce MTCT rates.

Indexed as

Anti-Retroviral AgentsBirth CohortCross-Sectional StudiesFemaleHIV InfectionsHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalLogistic ModelsMaleNigeriaPregnancyPregnancy Complications, InfectiousRetrospective StudiesSecondary Care CentersAnti-Retroviral Agents

Identifiers

PMID35157737
PMCPMC8843197
OpenAlexW4212972556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.